McKesson Corporation MCK SPXR3KPHARMA

Healthcare · Medical Distribution · United States

https://www.mckesson.com

Company Profile ↓

$907.99

+37.47% 1Y

Mkt Cap$105.86B

P/E24.34

P/B-23.79

Div. Yield0.43%

52W High$993.53

52W Low$660.48

Book Value$-36.55

EPS (TTM)$37.30

Company Overview

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 42.2%.

Reasonable Valuation

Trades at a P/E of 24.3, below the sector median of 25.2.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of $403.43B (+12.4% YoY); net profit $4.76B.
Trailing 12 Months Year-on-year growth — revenue +7.7%, earnings -17.6%.
5-Year Trend Long-term compounding — revenue CAGR 8.4%, profit CAGR 9.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	8.44%
1 Year:	7.70%

Compounded Profit Growth

5 Years:	9.68%
1 Year:	-17.60%

Stock Price Performance

1 Year:	+37.47%
6 Months:	-1.01%
3 Months:	+17.18%
1 Month:	+4.31%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 74% of range

$660.48 $993.53

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
Golden Cross2d ago
RSI (14)58.74 · Neutral

Price Performance

1M+4.31%

3M+17.18%

6M-1.01%

1Y+37.47%

Valuation vs Sector

P/E of 24.34 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Healthy ROCE of 42.2%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

24.34

Industry PE

25.17

Forward P/E

17.96

PEG Ratio

1.70

Book Value

$-36.55

Price to Book

-23.79

P/S

0.25

EV/EBITDA

15.69

Dividend Yield

0.43%

Growth (CAGR)

Revenue 5Y

8.44%

Profit 5Y

9.68%

Revenue (YoY)

7.70%

Earnings (YoY)

-17.60%

Profitability & Returns

ROCE

42.17%

ROE

ROA

4.74%

Profit Margin

1.12%

Op Margin

1.35%

Gross Margin

3.63%

EPS (Latest Qtr)

$5.15

EPS (TTM)

$37.30

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.50

Current Ratio

0.89

Debt

$11.80B

Total Assets

$88.33B

Current Assets

Working Capital

Ownership

Promoter Holding

0.06%

Chg in Prom Hold

0.01%

FII / Inst Holding

93.53%

Chg in FII Hold

-0.24%

Financial Snapshot

Enterprise Value

$105.86B

Total Revenue (TTM)

$410.98B

EBITDA

$7.07B

Free Cash Flow

$6.80B

Operating Cash Flow

$6.85B

Shares Outstanding

116.59M

Gross Margin

3.63%

Payout Ratio

8.80%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MCK McKesson Corporation SPXR3KPHARMA	907.99	24.34	$105.86B	0.43%	42.17%	-	8.44%	9.68%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Jun 2022	Sep 2022	Dec 2022	Jun 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Jun 2025	Sep 2025	Dec 2025	Jun 2026
Revenue	-	-	-	-	-	-	-	-	51.05B	52.06B	53.62B	51.63B	52.61B	53.08B	56.21B	52.43B	55.73B	57.62B	59.17B	58.53B	55.68B	60.81B	62.60B	59.14B	62.67B	66.58B	68.61B	67.15B	70.16B	70.49B	74.48B	77.22B	80.90B	79.28B	93.65B	95.29B	97.83B	103.15B	106.16B	105.38B
Gross Profit	2.85B	2.84B	2.87B	2.85B	2.91B	2.76B	2.81B	2.80B	2.56B	2.83B	2.71B	3.08B	2.78B	2.80B	2.97B	3.20B	2.79B	2.87B	3.03B	3.34B	2.70B	3.00B	3.15B	3.30B	3.03B	3.35B	3.43B	3.02B	3.10B	3.17B	3.02B	3.07B	3.15B	3.15B	3.25B	3.28B	3.28B	3.54B	3.69B	3.69B
Operating Income	931.00M	954.00M	920.00M	-	972.00M	580.00M	831.00M	-	633.00M	239.00M	834.00M	-	83.00M	689.00M	683.00M	-	634.00M	626.00M	360.00M	-	678.00M	634.00M	-7.36B	-	568.00M	539.00M	298.00M	1.04B	1.12B	1.24B	1.10B	951.00M	642.00M	1.03B	578.00M	1.22B	1.04B	1.41B	1.62B	1.32B
Net Income	576.00M	617.00M	634.00M	431.00M	542.00M	307.00M	633.00M	3.59B	309.00M	1.00M	903.00M	-1.15B	-138.00M	499.00M	469.00M	-796.00M	423.00M	-730.00M	186.00M	1.02B	444.00M	577.00M	-6.23B	666.00M	486.00M	267.00M	-7.00M	768.00M	926.00M	1.08B	958.00M	664.00M	589.00M	915.00M	241.00M	879.00M	784.00M	1.11B	1.19B	614.00M
Diluted EPS	2.45	2.63	2.73	1.88	2.38	1.34	2.85	16.76	1.45	0.01	4.33	-5.58	-0.68	2.51	2.40	-4.17	2.24	-3.99	1.03	5.85	2.72	3.54	-39.03	4.15	3.07	1.71	-0.04	5.26	6.42	7.66	7.02	4.92	4.42	7.00	1.87	6.95	6.25	8.92	9.59	5.15

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	101.70B	106.63B	108.70B	112.08B	122.32B	122.20B	137.39B	179.04B	190.88B	198.53B	208.36B	214.32B	231.05B	238.23B	-	276.71B	308.95B	359.05B	403.43B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	264.35B	296.12B	345.73B	388.88B
Gross Profit	5.01B	5.38B	5.68B	5.97B	6.40B	6.88B	8.35B	11.41B	11.42B	11.27B	11.18B	11.75B	12.02B	12.15B	-	12.36B	12.83B	13.32B	14.55B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.78B	8.66B	8.51B	8.10B
Operating Income	1.48B	1.20B	2.01B	1.82B	2.12B	2.35B	2.44B	2.97B	3.54B	7.12B	762.00M	886.00M	2.49B	-5.04B	-	4.58B	4.17B	4.82B	6.45B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.49B	4.68B	5.26B	7.18B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	248.00M	252.00M	265.00M	247.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.63B	3.79B	4.36B	6.20B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	905.00M	629.00M	878.00M	1.10B
Net Income	990.00M	823.00M	1.26B	1.20B	1.40B	1.34B	1.26B	1.48B	2.26B	5.07B	67.00M	34.00M	900.00M	-4.54B	-	3.56B	3.00B	3.29B	4.76B
Diluted EPS	3.32	2.95	4.62	4.57	5.59	5.59	5.41	6.27	9.70	22.73	0.32	0.17	4.95	-28.26	-	25.03	22.39	25.72	38.38
R&D Expense	347.00M	364.00M	376.00M	407.00M	402.00M	433.00M	457.00M	392.00M	392.00M	341.00M	125.00M	71.00M	96.00M	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2007	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	25.27B	28.19B	30.89B	33.09B	34.79B	51.76B	53.87B	56.52B	60.97B	60.38B	59.67B	61.25B	65.02B	63.30B	62.32B	67.44B	75.14B	82.32B
Total Equity	6.27B	6.12B	6.19B	7.53B	7.22B	6.83B	7.07B	8.52B	8.00B	8.92B	11.10B	9.80B	8.09B	5.09B	-21.00M	-2.27B	-1.86B	-1.97B	-2.07B	-2.17B
Cash & Equivalents	1.95B	1.36B	2.11B	3.73B	3.61B	3.15B	2.46B	4.19B	5.34B	4.05B	2.78B	2.67B	2.98B	4.01B	6.28B	3.53B	4.68B	4.58B	5.69B	3.98B
Long Term Debt	-	-	-	2.29B	3.59B	3.07B	4.87B	10.35B	9.71B	8.11B	8.36B	7.88B	7.59B	7.39B	7.15B	5.88B	5.59B	5.63B	5.65B	6.53B
Current Liabilities	-	-	15.61B	17.01B	18.73B	21.69B	21.36B	29.61B	33.50B	35.07B	35.61B	36.69B	37.63B	42.62B	44.10B	48.47B	47.96B	52.36B	61.60B	67.02B

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	869.00M	1.35B	2.32B	2.34B	2.95B	2.48B	3.14B	3.11B	3.67B	4.74B	4.34B	4.04B	4.37B	4.54B	4.43B	5.16B	4.31B	6.08B	6.16B
Investing Cash Flow	-5.00M	-727.00M	-309.00M	-624.00M	-1.50B	-2.21B	-5.05B	-677.00M	-1.56B	-3.27B	-2.99B	-1.38B	-579.00M	-415.00M	-89.00M	-542.00M	-1.07B	-733.00M	-3.43B
Financing Cash Flow	-1.47B	178.00M	-421.00M	-1.84B	-1.91B	-956.00M	3.62B	-968.00M	-3.45B	-2.07B	-3.08B	-2.23B	-2.73B	-1.69B	-6.32B	-4.37B	-3.34B	-3.96B	-4.63B
Capital Expenditure	-195.00M	-195.00M	-199.00M	-233.00M	-221.00M	-241.00M	-278.00M	-376.00M	-488.00M	-404.00M	-405.00M	-426.00M	-362.00M	-451.00M	-388.00M	-390.00M	-431.00M	-537.00M	-436.00M
Free Cash Flow	674.00M	1.16B	2.12B	2.10B	2.73B	2.24B	2.86B	2.74B	3.18B	4.34B	3.94B	3.61B	4.01B	4.09B	4.05B	4.77B	3.88B	5.55B	5.72B
Share Buybacks	-	-	323.00M	2.05B	1.87B	1.21B	130.00M	450.00M	1.61B	2.31B	1.71B	1.64B	1.93B	742.00M	3.52B	3.64B	3.02B	3.15B	4.75B
Dividends Paid	70.00M	116.00M	131.00M	171.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Mar 2008	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	4.9%	5.0%	5.2%	5.3%	5.2%	5.6%	6.1%	6.4%	6.0%	5.7%	5.4%	5.5%	5.2%	5.1%	-	4.5%	4.2%	3.7%	3.6%
Operating Margin %	1.5%	1.1%	1.8%	1.6%	1.7%	1.9%	1.8%	1.7%	1.9%	3.6%	0.4%	0.4%	1.1%	-2.1%	-	1.7%	1.4%	1.3%	1.6%
Net Margin %	1.0%	0.8%	1.2%	1.1%	1.1%	1.1%	0.9%	0.8%	1.2%	2.6%	0.0%	0.0%	0.4%	-1.9%	-	1.3%	1.0%	0.9%	1.2%
ROE %	16.2%	13.3%	16.8%	16.6%	20.5%	18.9%	14.8%	18.4%	25.3%	45.7%	0.7%	0.4%	17.7%	21,614.3%	-	-191.7%	-152.3%	-158.9%	-219.2%
ROCE %	-	12.4%	18.0%	15.0%	18.6%	17.5%	11.0%	14.6%	16.5%	28.1%	3.2%	4.0%	13.4%	-24.1%	-	31.9%	27.6%	35.6%	42.2%

Shareholding Pattern

Insiders

0.06%

Institutions

93.53%

Public Float

93.59%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.26%	10.80M	$9.64B
2	Vanguard Capital Management LLC	6.74%	7.85M	$7.02B
3	State Street Corporation	4.91%	5.73M	$5.12B
4	Morgan Stanley	4.55%	5.31M	$4.74B
5	Franklin Resources, Inc.	2.49%	2.91M	$2.60B
6	Vanguard Portfolio Management LLC	2.46%	2.87M	$2.57B
7	Geode Capital Management, LLC	2.42%	2.82M	$2.52B
8	Massachusetts Financial Services Co.	2.10%	2.45M	$2.19B
9	FMR, LLC	1.83%	2.13M	$1.90B
10	JPMORGAN CHASE & CO	1.50%	1.75M	$1.56B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MCK

Google News Fri, 04 Sep 2026

McKesson Corp (MCK) Stock Price, Quote, News & History - Benzinga

<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTFB5NWVfMmNoZVktcFpNbEdkdmpaQWhUbFF6cWdQZnRiaXVUUXpwV29kaFY4aHItSzNCR1Q3RHRiSGI0SGJvY05fZV9n?oc=5" target="_blank">McKesson Corp (MCK) Stock Price, Quote, News & History</a> &nb…

Google News hu, 20 Aug 2026

McKesson (MCK) Stock May Trade At A Discount As Cash Flow Holds Up - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQVFZHSHA1NUpPZC1CcUNrLUFfM1lQanZ4aVFuMTJOelktT08wU1J1NHAzdkE5NFpEVERVeVA2ZHQxbmpvemRNc0dHTXhIcVEwQzRUYkxFQjE5TEo5bk5PbnZIT0JSWjFDazlISGdyVVJwbVpxb09FVDBaT3pSSFRtZUdPZDJnTS1ndzgwWX…

Google News Fri, 04 Sep 2026

Mckesson Stock Price Forecast. Should You Buy MCK? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE9uWk9YdnBjemZ6eTdXLTNRb3JZMjBpNTNZdHdETGpBdkI0YTNBcUYtcFdPdm40VHVoc0VNbUExTU1lT29pT24w?oc=5" target="_blank">Mckesson Stock Price Forecast. Should You Buy MCK?</a>  <font…

Google News Sat, 05 Sep 2026

McKesson Stock (MCK) Opinions on Recent Data Leak and Market Dynamics - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNODNldmZzbVlKSXRET1lVXzJ4dnpIc1hON2FxX25vU29ZSWRIckUyU2VuTVByQUdYVGNfT1hWWXl2V2tPU3paTWptRXF0bGNGR3RBNmEyQW9WS2I1UjRvckFPWlEyNjE0cmo0QkNLc1JzVkdlVnowb3hHc0NYWnNoQmwwMWN1MWVlN09lVj…

Google News Fri, 04 Sep 2026

McKesson Stock: Is MCK Outperforming the Healthcare Sector? - Barchart.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPY3dzRnhrSVA4UGZueEZoa1NNN2ZCZWpaTlhpdTBJTEhscURaLTZKeFpIaUw0RzFSVHk3eEdnb0JrQ1FxSnVKVTQ5dlV4REdad3ZtM0hWODFqcUlpRWZvUFQtbHBRN0RFTWliRGZrN3h4enp1TnFaRVNMY1FHbEx4MFBqQi1hc1dsMlAwRW…

Google News hu, 03 Sep 2026

Mckesson Corporation (MCK) News, Articles, Events & Latest Updates - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTFBJWm5ONC1nU0RXVXRibDI2Q3lxcEFHaVFRNVZDcFZQQlJLNzg2X184TEJybHpQUGxEamJTbTFJZUp4OXF5QzBNUTNEMmZqY2s?oc=5" target="_blank">Mckesson Corporation (MCK) News, Articles, Events & Latest U…

MCK — Frequently Asked Questions

What is the current share price of McKesson Corporation (MCK)?

As of 2026-09-07 16:24 PDT, McKesson Corporation (MCK) trades at $907.99 on NYSE. Its 52-week range is $660.48 to $993.53.

What is the market capitalisation of MCK?

McKesson Corporation (MCK) has a market capitalisation of $105.86B on NYSE.

What is the P/E ratio of MCK?

MCK trades at a trailing price-to-earnings (P/E) ratio of 24.34. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -23.79.

Does MCK pay a dividend?

McKesson Corporation (MCK) currently offers a dividend yield of 0.43%.

Is MCK a good stock to buy?

This page provides a data-driven analysis of McKesson Corporation (MCK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

McKesson Corporation MCK SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

McKesson Corp (MCK) Stock Price, Quote, News & History - Benzinga

McKesson (MCK) Stock May Trade At A Discount As Cash Flow Holds Up - Yahoo Finance

Mckesson Stock Price Forecast. Should You Buy MCK? - StockInvest.us

McKesson Stock (MCK) Opinions on Recent Data Leak and Market Dynamics - quiverquant.com

McKesson Stock: Is MCK Outperforming the Healthcare Sector? - Barchart.com

Mckesson Corporation (MCK) News, Articles, Events & Latest Updates - Stocktwits

MCK — Frequently Asked Questions

What is the current share price of McKesson Corporation (MCK)?

What is the market capitalisation of MCK?

What is the P/E ratio of MCK?

Does MCK pay a dividend?

Is MCK a good stock to buy?

Explore More